Covid-19 ve Kanser

Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Et al. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med. 2020;27.

Chavez S, Long B, Koyfman A, Liang SY. Coronavirus disease (COVID-19): a primer for emergency physicians. Am J Emerg Med. 2020.

Garassino, M.C., Whisenant, J.G., Huang, L.C., Trama, A., Torri, V., Agustoni, F. Et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of aninternational, registry-based, cohort study. Lancet Oncol. 21, 914 922.https://doi.org/10.1016/S1470-2045(20)30314-4

Kuderer, N.M., Choueiri, T.K., Shah, D.P., Shyr, Y., Rubinstein, S.M., Rivera, D.R., et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395, 1907–1918.https://doi.org/10.1016/S0140-6736(20)31187-9

Schrag, D., Hershman, D.L., Basch, E., 2020. Oncology Practice during the COVID-19 Pandemic. JAMA- J. Am. Med. Assoc.https://doi.org/10.1001/jama.2020.6236

Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol.https://doi.org/10.1016/S1470-2045(20)30096-

Rogado, J., Obispo, B., Pangua, C., Serrano-Montero, G., Martín Marino, A., Pérez-Pérez, M. Et al. COVID-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid. Clin. Transl. Oncol. https://doi.org/10.1007/s12094-020-02381-z

Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C.E., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436. https://doi.org/10.1038/s41586-020-2521-4

Stopsack, K.H., Mucci, L.A., Antonarakis, E.S., Nelson, P.S., Kantoff, P.W., 2020.TMPRSS2 and COVID-19: Serendipity or opportunity for intervention? Cancer Discov. 10, 779–782. https://doi.org/10.1158/2159-8290.CD-20-0451

Jiawei Chen , Quanlong Jiang , Xian Xia , Kangping Liu , Zhengqing Yu , Wanyu Tao et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell 2020 Jul;19(7): e13168. Doi: 10.1111/acel.13168. Epub 2020 Jun19

Booeshaghi, A.S., Pachter, L., 2020. Decrease in ACE2 mRNA expression in aged Mouse lung. bioRxiv 2020.04.02.021451. https://doi.org/10.1101/2020.04.02.021451

Lucas, J.M., Heinlein, C., Kim, T., Hernandez, S.A., Malik, M.S., True, L.D., et al. 2014. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promote prostate cancer metastasis. Cancer Discov. 4, 1310–1325. https://doi.org/10.1158/2159-8290.CD-13-1010

Mehdi Baratchian,1 Jeffrey M. McManus,1 Mike Berk,1 Fumihiko Nakamura,1 Sanjay Mukhopadhyay,2 Weiling Xu, et al. Individual variation of the SARS-CoV-2 receptor ACE2gene expression and regulation bioRxiv. Preprint. 2020 Oct doi: 10.1101/2020.04.21.051201.

Montopoli, M., Zumerle, S., Vettor, R., Rugge, M., Zorzi, M., Catapano, C et al.2020. Androgen-deprivation therapiesfor prostate cancer and risk ofinfection by SARS-CoV-2: a population-based study (N:4532). https://doi.org/10.1016/j.annonc.2020.04.479

Richard S. Hotchkiss, M.D., and Steven M. Opal, M.D. March 26, 2020.ActivatingImmunityto Fight a Foe — A New Path: N Engl J Med 2020; 382:1270-1272 DOI: 10.1056/NEJMcibr1917242

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ.2020;27:1451–4.

Fung, M., Babik, J.M., 2020. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa863

Mangalmurti, N., Hunter, C.A., 2020. Cytokine Storms: Understanding COVID-19.Immunity. https://doi.org/10.1016/j.immuni.2020.06.017

Garvin, M.R., Alvarez, C., Miller, J.I., Prates, E.T., Walker, A.M., Amos, B.K., Mast, A.E, Justice, A., Aronow, B., Jacobson, D., 2020. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife 9. https://doi.org/10.7554/eLife.59177

Swann, J.B., Smyth, M.J., 2007. Immune surveillance of tumors. J. Clin. Invest. https://doi.org/10.1172/JCI31405

Coussens, L.M., Werb, Z., 2002. Inflammation and cancer. Nature. https://doi.org/10.1038/nature01322

Postow, M.A., Sidlow, R., Hellmann, M.D., 2018. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378, 158–168. https://doi.org/10.1056/NEJMra1703481

Robilotti, E. V., Babady, N.E., Mead, P.A., Rolling, T., Perez-Johnston, R, Bernardes, M., et al, 2020. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 26, 1218–1223. https://doi.org/10.1038/s41591-020-0979-0o,

Luo, Jia, Rizvi, H., Egger, J. V., Preeshagul, I.R., Wolchok, J.D., Hellmann, M.D., 2020. Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-20-0596

Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., et al; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy.JAMA. 2020;323(16):1574 1581. Doi:10.1001/jama.2020.5394

Argenzian, M.G., Bruc, S.L., Slate, C.L., Tia, J.R., Baldwi, M.R., Barr, R.G., et al., 2020. Characterization andclinical course of 1000 patients with coronavirus disease 2019 in New York: Retrospective case series. BMJ 369. https://doi.org/10.1136/bmj.m1996

Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., et al 2020. Patients with cancer appearmore vulnerable to SARS-CoV-2: A multicenter study during the COVID-19outbreak. Cancer Discov. 10, 783. https://doi.org/10.1158/2159-8290.CD-20-0422

Mehta, V., Goel, S., Kabarriti, R., Cole, D., Goldfinger, M., Acuna-Villaorduna, A. Et al. 2020. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 10, 935–941. https://doi.org/10.1158/2159-8290.CD-20-0516

Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., et al, 2020. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA- J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.3786

Mallett S, Allen AJ, Graziadio S, Taylor SA, Sakai NS Green K. et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data. BMC Med 2020; 18:346

Connors, J. M. & Levy, J. H. Thromboinflammation and the hypercoagulability of COVID-19. J. Thromb. Haemost. 18, 1559–1561 (2020)

Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., et al, 2020. Incidence of thrombotic complications incritically ill ICU patients with COVID-19. Thromb. Res. 191, 145.https://doi.org/10.1016/j.thromres.2020.04.013

Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A.S., Mehra, M.R., Schuepbach, R.A., Ruschitzka, F., Moch, H., 2020.Endothelial cell infection and endotheliitis in COVID-19. Lancet.https://doi.org/10.1016/S0140-6736(20)30937-5

Lee, A.Y.Y., 2003. Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation 107, 17I--21. https://doi.org/10.1161/01.CIR.0000078466.72504.AC

Falanga A, Russo L, Verzeroli C. Mechanismsof thrombosis in cancer. Thromb Res.2013;131(Suppl 1): S59 S62.

Moll M, Zon RL, Sylvester KW, Chen EC, Cheng V, Connell NT, et al. VTE in ICU patients with COVID-19. Chest. 2020. https://doi. org/10.1016/j.chest.2020.07.031.

Patel P, Patel P, Bhatt M, Braun C, Begum H, Nieuwlaat R et al. Systematic review and meta-analysis of outcomes in patients with suspected deep vein thrombosis. Blood Adv 2020; 4:2779-88. 10.1182/bloodadvances.2020001558

Flodgren, G., Rachas, A., Farmer, A.J., Inzitari, M., Shepperd, S., 2015. Interactive telemedicine: Effects on professional practice and health care outcomes. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD002098.pub2

Flaxman S, Mishra S, Gandy A, H. Juliette T. Unwin, Thomas A. Mellan, Helen Coupland et al. Estimating the effects of nonpharmaceutical interventions on COVID-19 in Europe. Nature. Published online June 8, 2020.doi:10.1038/s41586- 020-2405-7

Maringe, C., Spicer, J., Morris, M., Purushotham, A., Nolte, E., Sullivan, R et al., 2020. The impact of the COVID-19 pandemic on cancerdeaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 0. https://doi.org/10.1016/S1470- 2045(20)30388-0

Sud, A., Jones, M.E., Broggio, J., Loveday, C., Torr, B., Garrett, A., et al.2020. Collateraldamage: the impact on outcomes from cancer surgery of the COVID-19pandemic. Ann. Oncol. https://doi.org/10.1016/j.annonc.2020.05.009

Xie C, Wang X, Liu H, Bao Z, Yu J, Zhong Y, et al. Outcomes in radiotherapy-treated patients with cancer during the COVID-19 outbreak in Wuhan, China. JAMA Oncol. 2020; e202783.

Rubinstein, S.M., Warner, J.L., 2020. COVID-19 and haematological malignancy: navigating a narrow strait. Lancet Haematol. 0. https://doi.org/10.1016/s2352- 3026(20)30252-0

Pinato DJ, Lee AJX, Biello F, Segui E, Aguilar-Company J, Carbo A et al. Presenting features and earlymortality from SARS-CoV-2 infection in cancer patients duringthe initial stage of the COVID-19 pandemic in Europe. Cancers (Basel)2020;12(7): E1841.https://doi.org/10.3390/-cancers12071841. Published 2020 Jul 8.

Tian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., et al 2020.Clinical characteristics and risk factors associated with COVID-19 diseaseseverity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 21, 893–903. https://doi.org/10.1016/S1470-2045(20)30309-0

Yancy, C.W., 2020. COVID-19 and African Americans. JAMA- J. Am. Med. Assoc. https://doi.org/10.1001/jama.2020.6548

Rivera, D.R., Peters, S., Panagiotou, O.A., Shah, D.P., Kuderer, N.M., Hsu, C.-Y, et al, 2020. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: ACOVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discov. 1, CD-20-0941. https://doi.org/10.1158/2159-8290.cd-20-0941

Balogun, O.D, Bea, V.J., Phillips, E., 2020. Disparities in Cancer Outcomes Due to COVID-19—A Tale of 2 Cities. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.3327

NCCN. Coronavirus disease 2019 (COVID-19) resources for the cancer care community. [Cited 2020 Apr 9]; available from: https://www.nccn.org/COVID-19/.

ASCO. ASCO coronavirus resources. [Cited 2020 Apr 9]; available from: https://www.asco.org/asco-coronavirus-information

ESMO. ESMO COVID-19 and cancer. [Cited 2020 Apr 9]; available from: https://www.esmo.org/COVID-19-and-cancer.

Del Valle, D.M., Kim-Schulze, S., Huang, H.-H., Beckmann, N.D., Nirenberg, S., Wang, B., et al 2020. An inflammatory cytokine signaturepredicts COVID-19 severity and survival. Nat. Med. 1–8.https://doi.org/10.1038/s41591-020-1051-9

Wynants, L., Van Calster, B., Collins, G.S., Riley, R.D., Heinze, G., Schuit, E et al 2020. Prediction models for diagnosis and prognosis of COVID-19: Systematic review and critical appraisal. BMJ 369,18.https://doi.org/10.1136/bmj.m1328